This 75-minute webinar will look at the ongoing development and distribution of COVID-19 vaccines and what this means for the global dementia community.
Featured news and events
ADI's Global Perspective for February 2020 now available.
Roche announces end of DIAN-TU-001 study after it failed to meets its primary endpoint in people who are affected by early onset Autosomal dominant Alzheimer’s disease.
hinese Pharmaceutical Company Green Valley announces their drug Oligomannate (GV-971) has been granted conditional approval for the treatment of "mild to moderate Alzheimer's disease".
Biogen and Eisai have announced they will file for market approval for an investigational treatment for early Alzheimer’s disease.
Ahead of the G20 Health Ministers Meeting in Okayama, ADI’s Chief Executive Paola Barbarino and Noriyo Washizu of Alzheimer's Association Japan (AAJ) continue to work on progress made earlier in the year at the Osaka Summit.
Ahead of the G20 Health Ministers Meeting in Okayama, ADI Chief Executive Paola was interviewed by one of Japan's largest newspaper.
The Spanish Ministry of Health, Consumption and Social Welfare has announced that they have adopted a national dementia plan.
Results from the world’s largest survey reveals that stigma around dementia is preventing people from seeking the information, advice, support and medical help.